D. Boral Capital Maintains Buy on NeuroSense Therapeutics, Maintains $14 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
D. Boral Capital analyst Jason Kolbert maintains NeuroSense Therapeutics (NASDAQ:NRSN) with a Buy and maintains $14 price target.
